ArticleCommunications biology2025
tRF16 affects NFKBIA stability and promotes osteoarthritis progression by regulating ALKBH5 expression in m6A-dependent manner.
Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Methylation regulatory networks in osteoarthritis: mechanisms and targeted therapies.Journal of translational medicine · 2026Review
- CAP-CD56Bioactive materials · 2026Article
- Xinfeng capsule improves hyperinflammation-associated hypercoagulability and self-perception in osteoarthritis by regulating KLF4 through METTL14-mediated mFrontiers in immunology · 2026Article
- METTL3 promotes chondrocyte injury in osteoarthritis by increasing CTSB expression.Journal of orthopaedic surgery and research · 2025Article
- Conserved small RNA networks link inflammation to pain signaling in mice and men.Translational psychiatry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to investigate explore the role of tRF16-ALKBH5 in osteoarthritis (OA). Differential expression of tRF in normal and OA tissues was analyzed using sequencing. OA rats model was established by destabilization of the medial meniscus and anterior cruciate ligament transaction surgeries. The tRF-16 inhibitor or mimic was injected into OA rats and OA symptoms were analyzed. We analyzed the m6A levels in tRF16 inhibitor-treated rat cartilage tissues, ALKBH5 levels, and the binding relationship between tRF16 and ALKBH5. The effect of ALKBH5 on OA rats was analyzed using specific antagonists. Chondrocytes were extracted to establish an OA cell model using IL-1β induction. The effects of tRF16, ALKBH5, and downstream genes on chondrocyte viability were verified. tRF-16 was overexpressed in OA patients and rat models. tRF16 inhibitor improved the symptoms of OA rats and inhibited autophagy and extracellular matrix degradation in IL-1β-induced chondrocytes. tRF16 reduced ALKBH5 expression by targeting ALKBH5, decreased NFKBIA mRNA stability, and activated the NF-kB pathway, thus exacerbating OA progression. Collectively, by binding to ALKBH5, tRF16 promotes the degradation of ALKBH5 and impairs the maintenance of NFKBIA mRNA stability by ALKBH5, promotes the nuclear translocation of phos-p65, leads to the secretion of inflammatory factors, exacerbates OA symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.